Health Care [ 6/12 ] | Health Care Technology [ 22/74 ]
NASDAQ | Common Stock
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool.
Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software.
Certara I
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | 0.15 Increased by +66.67% | 0.13 Increased by +19.62% |
| Nov 6, 24 | 0.13 Increased by +18.18% | 0.11 Increased by +18.18% |
| Aug 6, 24 | 0.07 Decreased by -41.67% | 0.10 Decreased by -30.00% |
| May 7, 24 | 0.10 Decreased by -16.67% | 0.10 |
| Feb 29, 24 | 0.09 Decreased by -43.75% | 0.11 Decreased by -18.18% |
| Nov 8, 23 | 0.11 Increased by +10.00% | 0.11 |
| Aug 9, 23 | 0.12 Increased by +33.33% | 0.13 Decreased by -7.69% |
| May 8, 23 | 0.12 Increased by +9.09% | 0.12 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 100.36 M Increased by +14.03% | 6.58 M Increased by +152.80% | Increased by +6.55% Increased by +146.30% |
| Sep 30, 24 | 94.82 M Increased by +10.80% | -1.37 M Increased by +97.20% | Decreased by -1.45% Increased by +97.47% |
| Jun 30, 24 | 93.31 M Increased by +3.17% | -12.57 M Decreased by -367.19% | Decreased by -13.48% Decreased by -358.99% |
| Mar 31, 24 | 96.65 M Increased by +7.04% | -4.68 M Decreased by -444.85% | Decreased by -4.85% Decreased by -422.18% |
| Dec 31, 23 | 88.01 M Increased by +1.59% | -12.46 M Decreased by -235.78% | Decreased by -14.15% Decreased by -233.65% |
| Sep 30, 23 | 85.58 M Increased by +1.03% | -48.97 M Decreased by -1.34 K% | Decreased by -57.22% Decreased by -1.33 K% |
| Jun 30, 23 | 90.45 M Increased by +9.29% | 4.71 M Increased by +898.98% | Increased by +5.20% Increased by +831.05% |
| Mar 31, 23 | 90.30 M Increased by +10.73% | 1.36 M Decreased by -38.55% | Increased by +1.50% Decreased by -44.51% |